Neuberger Berman Group LLC Has $10.77 Million Position in Haleon PLC Sponsored ADR (NYSE:HLN)

Key Points

• Neuberger Berman Group LLC increased its stake in Haleon PLC by 9.1% during the first quarter, bringing its total value to approximately $10.77 million.
• A semi-annual dividend of $0.0555 per share has been announced, reflecting an increase from the previous dividend of $0.05, with a payout ratio of 64.10%.
• The stock received varied analyst ratings, with a consensus rating of "Moderate Buy" and an average price target of $12.33 from multiple financial institutions.

Neuberger Berman Group LLC lifted its holdings in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 9.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,047,009 shares of the company's stock after acquiring an additional 87,116 shares during the period. Neuberger Berman Group LLC's holdings in Haleon were worth $10,774,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Nuveen LLC bought a new stake in Haleon during the first quarter worth about $58,870,000. Northern Trust Corp lifted its holdings in shares of Haleon by 27.7% in the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after acquiring an additional 1,172,931 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Haleon in the fourth quarter worth about $45,110,000. Bain Capital Public Equity Management II LLC lifted its holdings in shares of Haleon by 6.2% in the fourth quarter. Bain Capital Public Equity Management II LLC now owns 2,844,010 shares of the company's stock worth $27,132,000 after acquiring an additional 165,929 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Haleon by 62.6% in the fourth quarter. Royal Bank of Canada now owns 2,733,615 shares of the company's stock worth $26,078,000 after acquiring an additional 1,052,462 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Trading Down 0.6%

Shares of HLN stock traded down $0.06 during trading hours on Friday, hitting $9.64. 7,875,929 shares of the company were exchanged, compared to its average volume of 10,981,824. The firm has a market cap of $43.27 billion, a P/E ratio of 24.72, a P/E/G ratio of 2.85 and a beta of 0.23. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a 50 day simple moving average of $10.04 and a two-hundred day simple moving average of $10.21.

Haleon Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Thursday, September 18th. Investors of record on Friday, August 15th will be given a $0.0555 dividend. This represents a yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. This is an increase from Haleon's previous semi-annual dividend of $0.05. Haleon's payout ratio is 28.21%.

Wall Street Analyst Weigh In

HLN has been the subject of a number of research reports. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a report on Friday, May 9th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Finally, BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.